Gc

GC Holdings, converted to a pure holding company structure in 2001, oversees a total of 54 group affiliates (33 domestic and 21 overseas) and generates income mainly from managing and supporting subsidiaries plus building rental, without direct business operations of its own.

Its core operating subsidiary is GC Biopharma, centered on plasma-derived blood products and vaccines, where the U.S. launch of the immunoglobulin product Alyglo has been expanding overseas blood-product sales, and the varicella vaccine Barysela has obtained WHO prequalification to broaden its export reach.

The Hunter syndrome treatment Hunterase is sold in more than ten countries, while the hemophilia treatment Green Gene F has secured product approval in China and is expanding into that market.

GC Cell, which handles cell therapy and clinical laboratory testing services, and ABO Holdings, a U.S. plasma-collection affiliate, are also key group subsidiaries.

In March 2026, the holding company directly acquired GC Biopharma's entire stake in GC Wellbeing, a nutrition, health-supplement and aesthetics business, simplifying the dividend flow that previously passed through GC Biopharma before reaching the holding company.

The group also has ties to Curevo, a vaccine-development biotech affiliate, which is being acquired by a global pharmaceutical company as part of an ongoing portfolio reshuffling. The holding company is led by co-CEO Huh Yong-jun, with Chairman Huh Il-sup and related parties together holding roughly 49% of shares.

Consolidated revenue reached KRW 2.4515 trillion in 2025, up 11.2% from KRW 2.2049 trillion in 2024, and operating profit turned positive at KRW 36.2 billion, reversing consecutive operating losses of -KRW 10.7 billion in 2024 and -KRW 16.4 billion in 2023.

Net income attributable to owners, however, widened to -KRW 41.8 billion from -KRW 11.1 billion in 2024, suggesting non-operating items weighed heavily on the bottom line.

On a quarterly basis, 2025Q3 was solid with revenue of KRW 736.9 billion, operating profit of KRW 26.0 billion and owner net income of KRW 9.2 billion, but 2025Q4 saw revenue slip to KRW 619.5 billion with operating profit swinging to -KRW 6.7 billion and owner net income posting a sharp -KRW 87.8 billion loss that significantly dented the full-year result.

Moving into 2026, operating profit showed a modest recovery with KRW 3.1 billion in Q1 (revenue KRW 534.8 billion) and KRW 6.6 billion in Q2 (revenue KRW 596.3 billion), yet owner net income remained negative for a fourth straight quarter at -KRW 17.3 billion and -KRW 11.0 billion, respectively.

Over the trailing four quarters (2025Q3-2026Q2), cumulative owner net income totaled -KRW 107.0 billion, a notable gap versus cumulative operating profit of roughly KRW 29.0 billion, pointing to substantial non-operating drag.

On the balance-sheet side, the debt ratio jumped to 130.7% at end-2025 from 98.2% at end-2024, partly reflecting funding needs tied to the GC Wellbeing stake acquisition and other subsidiary restructuring.

Operating cash flow, however, improved to KRW 24.3 billion in 2025 from a large outflow of -KRW 89.9 billion in 2024, signaling recovering cash-generation capacity.

Given that 2022 was profitable with revenue of KRW 2.0796 trillion, operating profit of KRW 71.2 billion and owner net income of KRW 32.8 billion, the persistent net losses over 2023-2025 can be viewed as earnings volatility tied to group-wide portfolio restructuring and investment expansion.

In the plasma-derived products and vaccine industry, competitiveness is largely determined by domestic self-sufficiency policy and the ability to secure source plasma amid an oligopolistic global competitive landscape dominated by large multinational players.

GC Biopharma operates Korea's only dedicated vaccine production facility (the Hwasun plant) and one of Asia's largest plasma-fractionation and recombinant-protein production facilities (the Ochang plant), while securing plasma supply through its U.S. affiliate ABO Holdings.

In the U.S. immunoglobulin market, dominated by large global players such as CSL Behring, Takeda, and Grifols, Alyglo is in the process of establishing itself as a later entrant.

In vaccines, the company has been building a position in international procurement markets through WHO prequalification and supply contracts with the Pan American Health Organization (PAHO) and the Thai government for influenza vaccines.

The cell therapy and diagnostic testing segment (GC Cell) operates in an industry marked by intensifying domestic diagnostic-service competition and ongoing R&D investment burdens, though a recent restructuring of its revenue base has notably led to a return to profitability.

At the holding-company level, group strategy is being reorganized to transfer non-core assets (GC Wellbeing) to the holding company while concentrating funding on core businesses such as blood-product R&D, aligning with a broader trend of portfolio streamlining seen among domestic pharmaceutical and bio holding companies.

In a February disclosure, GC Holdings established a mid-term dividend policy to return at least 50% of the three-year average standalone net income to shareholders for fiscal years 2026-2028, while GC Biopharma has set its own policy to distribute at least 20% of standalone net income for 2025-2027.

On governance, GC Biopharma removed the cumulative-voting exclusion clause at its March 2026 shareholders' meeting, with cumulative voting set to take effect from September 10, 2026, signaling a shift toward strengthened minority shareholder rights.

On the operating side, as seen in 2026Q2 results, flu vaccine bulk revenue normally recognized in the second quarter was pushed to the third quarter due to delays in securing WHO-designated reference strain standards, with the affected volume fully shipped in July and set to be reflected in third-quarter results, while Hunterase overseas sales are also expected to be concentrated in the second half, according to the company.

Alyglo posted 2026Q2 sales of KRW 40.5 billion, up about 10% from the first quarter, and the company expects to reach its full-year sales target of $150 million.

Group affiliate Curevo was reported in late May 2026 to be acquired by a global pharmaceutical company for up to $1.5 billion, and if the share transfer originally scheduled for August 24 proceeded as planned, the resulting cash inflow along with binding CMO and royalty arrangements could affect the group's financial structure, according to a Kiwoom Securities report dated May 28, 2026.

GC Cell achieved its first quarterly net profit in roughly two years in 2026Q2 through a restructuring centered on clinical laboratory testing services and management efficiency improvements, and stated it aims for a full-year turnaround driven by second-half growth.

Whether these deferred segment revenues materialize in the second half and whether the dividend policy is actually implemented will likely be key variables shaping future earnings and shareholder returns.